Category: ACN Newswire

SAN FRANCISCO, CA & MUMBAI, Dec 2, 2024 - (ACN Newswire via SeaPRwire.com) - CleverTap, the all-in-one engagement platform, has released its market research report on “The State of App and Web User Experience Optimization”. The report sheds light on how digital-first brands are leveraging experimentation and personalization on their apps and websites to drive customer engagement and business growth. It also highlights roadblocks faced by marketers and product managers while experimenting with the UI, workflows, and functionality across apps and websites.For a thorough understanding of the current landscape, this report draws insights from a diverse group of respondents – with data gathered through structured surveys and in-depth interviews – representing organizations with over two million customers across 50+ countries. This includes VPs, CMOs, and product managers ranging from startups to large enterprises across various industries. – Together, they offer valuable insights into how businesses optimize app and web experiences to drive customer engagement and business growth.While 95% of surveyed product managers and 88% of marketers believe that the right user experience is essential for driving customer engagement and retention — many report significant challenges to effectively experimenting with app and web user experiences. Despite recognizing its importance, they reported difficulties such as limited resources, data gaps, and technical constraints that hinder their ability to innovate and deliver impactful user experiences. Other notable findings from the report include -81.9% of product managers rarely experiment with their app and web experiences before making changes to them. The top challenges quoted include lack of resources (46%), inadequate data and analytics (31%), and technical issues (19%)54% of product managers are unable to support marketers in experimenting with onboarding flows, banner placement, homepage content and other similar app and web experiences.81% of marketers believe it would make a significant impact if they could independently experiment with multiple variations of web and app experiences within a no-code framework provided by their product management function.Commenting on the report, Jacob Joseph, Vice President - Data Science, CleverTap said, “With consumer expectations constantly rising, brands need to go beyond perfecting their channel strategies and also focus on enhancing the in-app and web experiences to drive results from their marketing efforts. Since all channels ultimately lead users to the app or website, an unsatisfactory experience there can render all your efforts ineffective and become a missed opportunity. Personalization and experimentation on apps and websites are critical to reducing churn and driving growth, yet resource constraints and data gaps hinder marketers and product managers. We are committed to helping businesses navigate these challenges with CleverTap’s Product Experiences, which offers effortless ways to personalize and experiment with app and web experiences driving stronger engagement and lasting brand loyalty."For more information and insights download the report here. About CleverTapCleverTap is the leading all-in-one customer engagement platform that helps brands unlock limitless customer lifetime value. CleverTap is trusted by over 2000 brands like Decathlon, Domino’s, Levis, Jio, Emirates NBD, Puma, Croma (A Tata Enterprise), Swiggy, SonyLIV, Axis Bank, AirAsia, TD Bank, Ooredoo, and Tesco to help build personalized experiences for all their customers. The platform is powered by TesseractDB™ – the world’s first purpose-built database for customer engagement, offering speed and cost efficiency at scale.Backed by top-tier investors such as Accel, Peak XV Partners, Tiger Global, CDPQ and 360 One, the company is headquartered in San Francisco, with presence across Seattle, London, São Paulo, Bogota, Mexico, Amsterdam, Sofia, Dubai, Mumbai, Bangalore, Singapore, Vietnam, and Jakarta.For more information, visit clevertap.com or follow us on:LinkedIn: https://www.linkedin.com/company/clevertap/ X: https://twitter.com/CleverTap Forward-Looking StatementsSome of the statements in this press release may represent CleverTap's belief in connection with future events and may be forward-looking statements, or statements of future expectations based on currently available information. CleverTap cautions that such statements are naturally subject to risks and uncertainties that could result in the actual outcome being absolutely different from the results anticipated by the statements mentioned in the press release.Factors such as the development of general economic conditions affecting our business, future market conditions, our ability to maintain cost advantages, uncertainty with respect to earnings, corporate actions, client concentration, reduced demand, liability or damages in our service contracts, unusual catastrophic loss events, war, political instability, changes in government policies or laws, legal restrictions impacting our business, impact of pandemic, epidemic, any natural calamity and other factors that are naturally beyond our control, changes in the capital markets and other circumstances may cause the actual events or results to be materially different, from those anticipated by such statements. CleverTap does not make any representation or warranty, express or implied, as to the accuracy, completeness, or updated or revised status of such statements. Therefore, in no case whatsoever will CleverTap and its affiliate companies be liable to anyone for any decision made or action taken in conjunction.For more information:SONY SHETTYDirector, Communications, CleverTap+91 9820900036sony@clevertap.comASHMIT CHAUDHARYAssociate Consultant, Archetype+91 8850752121ashmit.chaudhary@archetype.co Copyright 2024 ACN Newswire via SeaPRwire.com.

SHENZHEN, CHINA, Dec 2, 2024 - (ACN Newswire via SeaPRwire.com) - China Medical System Holdings Limited (the “Company”, together with its subsidiaries, the “Group” or “CMS”) is pleased to announce that on 2 December 2024, the Group through a wholly-owned subsidiary of the Company entered into an Exclusive Commercialization Agreement (the “Agreement”) with Atom Therapeutics Co., Ltd (hereinafter referred to as “Atom Therapeutics”, formerly named as “Jiangsu Atom Bioscience and Pharmaceutical Co., Ltd.”) of class 1 innovative drug ABP-671 for the treatment of gout and hyperuricemia (the “Product”). In accordance with the Agreement, the Group is entitled to an exclusive commercialization right of the Product in Mainland China, Hong Kong Special Administrative Region and Macao Special Administrative Region. The term of cooperation commences on the effective date of the Agreement and extends for ten years from the date the Product is first approved for market launch in Mainland China (the "Authorization Term"). Upon the expiration of the Authorization Term, it may be automatically renewed for an additional ten years, subject to specific conditions stipulated in the Agreement.ABP-671 is a class 1 innovative chemotherapeutic drug for the treatment of gout and hyperuricemia, currently in Phase 2b/3 clinical trials for gout in China and overseas. The Product reduces renal re-absorption of uric acid by inhibiting Urate Anion Transporter 1 (URAT1). The results of two completed phase 2 clinical trials demonstrated favorable efficacy and safety profiles across multiple dose groups (ranging from 1 mg to 12 mg) of ABP-671. The 2 mg once-daily dosage of the Product was proved to be as effective as, or even better than, benzbromarone or febuxostat (maximum dosage of 80mg). The reduction in uric acid levels was sustained throughout the 24-hour period, with no significant safety concerns identified. This product is anticipated to offer more effective and safer treatment alternatives for patients suffering from gout and hyperuricemia[1]. Multiple patents in regard to substance and use of the ABP-671 have been granted in China.Hyperuricemia is defined as a fasting blood uric acid level exceeding 420μmol/L (7.0 mg/dL) in adults on a normal purine diet on two separate days. The deposition of urate crystals in hyperuricemia patient results in arthritis, medically termed gout. Hyperuricemia and gout can cause acute and chronic inflammatory injury in articular cartilage, bone, kidney and vascular wall, which can lead to multiple organ damage of the heart, brain and kidney, etc. The data presented in the White Paper on Hyperuric Acid and Gout Trends in China (2021) indicates that, the incidence rate of hyperuricemia is 13.3%, with approximately 177 million hyperuricemia patients and the incidence rate of gout is 1.1% in general, with about 14.66 million gout patients in China. Frost & Sullivan indicates that, the number of people with hyperuricemia and gout in China will continue to increase in the future, reaching 240 million and 52.2 million respectively by 2030. Currently, the commonly used uric acid-lowering drugs in clinical practice in China are those which inhibit uric acid synthesis or promote uric acid excretion. Due to certain limitations in the efficacy and safety of the marketed uric acid-lowering drugs, such as causing renal failure, sudden cardiac death or severe liver toxicity. There is still an urgent need for effective and safe uric acid-lowering drugs among gout and hyperuricemia patients in China.ABP-671 is currently with the potential to be the promising and safe product for the treatment of gout and hyperuricemia. Through this collaboration, it fills the blank in the CMS's product portfolio of the treatment of gout. Gout and hyperuricemia are both rheumatic diseases and chronic metabolic diseases, which are highly consistent with the Group's strategic layout in the cardio-cerebrovascular/ gastroenterology business and the network resources of marketed products. If approved for marketing in the future, the Product will synergize with the Group’s marketed product Metoject (methotrexate injection) in rheumatology and with Elcitonin (elcatonin injection) in endocrinology and orthopedics, in terms of expert network and market resources. Based on the unmet clinical needs and the expected solid clinical data of the Product, the Group is looking forward to the smooth advancement of the clinical development of ABP-671, allowing patients with relevant indications to benefit from this innovative treatment sooner.About ATOM THERAPEUTICSAtom Therapeutics was founded in March 2012, focused on the research and development of innovative drugs with global commercial value and competitiveness in the metabolic and inflammatory area. Atom Therapeutics's main core team members come from the United States, with extensive experience in the research and development of innovative drugs. Atom Therapeutics has achieved remarkable development in the past few years. Atom Therapeutics's core product ABP-671 is under pivotal clinical stage for the treatment of chronic gout. Atom Therapeutics's another small molecule innovative drug named as ABP-745, used for indications in the field of anti-inflammatory immune indications. The Phase 1 clinical of ABP-745 exhibited outstanding pharmacokinetics and safety. The clinical trial is on the verge of entering Phase 2. For more information about Atom Therapeutics and its pipeline, please visit https://www.atombp.com/.About CMSCMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs.CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients.CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development of its advantageous specialty fields and expand business boundaries. While strengthening the competitiveness of the cardio-cerebrovascular/gastroenterology business, CMS independently operates its dermatology and medical aesthetics business, and ophthalmology business, aiming to gain leading positions in specialty therapeutic fields, whilst enhancing the scale and efficiency. At the same time, CMS has expanded its business territory to the Southeast Asian market, striving to become a "bridgehead" for global pharmaceutical companies to enter the Southeast Asian market, further escorting the sustainable and healthy development of the Group.Reference:1. The results of Phase 2 clinical trials was published and can be found at: https://www.atombp.com/2023/03/01/atom-bioscience-announces-positive-results-of-phase-2a-china-clinical-trial-of-its-urat1-inhibitor-for-chronic-gout/CMS Disclaimer and Forward-Looking StatementsThis press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert.This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections.Media ContactBrand: China Medical System Holdings Ltd.Contact: CMS Investor RelationsWebsite: https://web.cms.net.cn/en/home/Source: China Medical System Holdings Ltd. Copyright 2024 ACN Newswire via SeaPRwire.com.

SHANGHAI, Dec 2, 2024 - (ACN Newswire via SeaPRwire.com) - Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today announced that Department of Health of the Government of the Hong Kong Special Administrative Region, China, has accepted Everest’s New Drug Application (NDA) for VELSIPITY(R) (etrasimod) for the treatment of adult patients with moderately to severely active ulcerative colitis. VELSIPITY(R) is an effective and convenient, once-daily, oral treatment for patients with moderately-to-severely active UC that has already been approved in the U.S. and E.U., and other countries, by Everest’s licensing partner, Pfizer. In Everest territories, the Pharmaceutical Administration Bureau of the Macau Special Administrative Region, China has approved the NDA for VELSIPITY(R) in April of this year and was implemented in the Guangdong-Hong Kong-Macau Greater Bay Area this October through the "Hong Kong and Macau Medicine and Equipment Connect" policy."Autoimmune disease is a core focus and a significant growth driver for our company. The number of UC patients in China is projected to double from 2019 to 2030 to approximately one million, highlighting the urgent need for novel treatments." said Rogers Yongqing Luo, Chief Executive Officer of Everest Medicines. “Previously, VELSIPITY(R) has already been approved in Macau, China, and was implemented in the Greater Bay Area through the connect policy. The company also plans to submit the NDA for approval by China’s National Medical Products Administration (NMPA) this year, with the aim of benefiting more Chinese patients as soon as possible."" This is an important advancement for etrasimod, bringing hope to patients in Hong Kong, China. This new-generation S1P receptor modulator is an oral, once-daily treatment that can provide patients with a chance for corticosteroid-free remission, mucosal healing, and rapid symptom relief, " said Prof. Wu Kaichun with the First Affiliated Hospital of AFMU who is the principal investigator for etrasimod’s Asia clinical trial. “We hope China and other Asian countries can obtain approvals as soon as possible to benefit more patients."The acceptance of the NDA was based on results from the ELEVATE UC Phase 3 registrational program (ELEVATE UC 52 and ELEVATE UC 12) that evaluated the safety and efficacy of etrasimod 2 mg once-daily on clinical remission in UC patients with moderately to severely active UC who had previously failed or were intolerant to at least one conventional, biologic, or Janus kinase (JAK) inhibitor therapy. Nearly two-thirds of patients in ELEVATE UC 52 and ELEVATE UC 12 were naïve to biologic or JAK inhibitor therapy, and these studies were also the only studies for advanced therapies for ulcerative colitis to include patients with isolated proctitis. Both studies achieved all primary and key secondary efficacy endpoints, with a favorable safety profile consistent with previous studies of etrasimod.Everest conducted a multicenter, randomized, double-blind and placebo-controlled Phase 3 trial of etrasimod in Asian countries, including mainland China, China Taiwan and South Korea. This is the largest Phase 3 trial of moderately-to-severely active ulcerative colitis in Asia completed to date, with 340 eligible subjects randomized to treatment with etrasimod or placebo. The previously announced results of the induction period indicate that the clinical remission rate for patients treated with etrasimod 2mg was 25.0%, compared to 5.4% for those treated with placebo (difference 20.4%, p

SAN DIEGO, CA, Dec 3, 2024 - (ACN Newswire via SeaPRwire.com) - On November 19, 2024, General Atomics Aeronautical Systems, Inc. (GA-ASI) hosted its first Blue Magic Netherlands (BMN) event in Eindhoven, the Netherlands. Approximately 200 people attended the event that provided Dutch businesses with an opportunity to present their capabilities to GA-ASI and other companies interested in possible collaborations. GA-ASI was joined for the event by the Netherlands Ministry of Economic Affairs, the Netherlands Ministry of Defence, Lockheed Martin Ventures, Brainport Development, Brabant Development Agency (BOM), the Netherlands Industries for Defence & Security (NIDV), and SpaceNED.At this event, GA-ASI and its partners heard first-hand from Dutch companies about the important capabilities they are developing. The process started in July when GA-ASI put out an open invitation to Dutch businesses to apply for the opportunity to present innovative technologies at the November 19 event. Key areas of focus included Artificial Intelligence/Machine Learning, Autonomy, Advanced Materials, Sensors, Advanced Manufacturing, and Space. Close to 50 companies applied and after reviewing the applications, 15 businesses were selected to pitch their capabilities to an audience that included lightweight lattice structures, gas detection technologies, advanced battery and photonics applications, and several innovative unmanned system and AI applications, among many others."This event is where the rubber meets the road," said Brad Lunn, Managing Director-Strategic Finance at GA-ASI. "In addition to attracting many companies, we increased the areas of expertise and depth of knowledge from the presenting companies in order to provide research, development, and breakthrough innovations to support current and future missions by GA-ASI aircraft. We also wanted to give the companies an opportunity to pitch in front of other potential customers, partners, and investors."The first Blue Magic event held by GA-ASI was in 2019 in Belgium, with subsequent events held in 2020, 2021, and 2023. GA-ASI is delivering eight MQ-9A Remotely Piloted Aircraft to the Royal Netherlands Air Force (RNLAF).GA-ASI expects to announce technology partnerships stemming from the BMN event and intends to hold this event on an annual basis in the Netherlands.About GA-ASIGeneral Atomics Aeronautical Systems, Inc. (GA-ASI), an affiliate of General Atomics, is a leading designer and manufacturer of proven, reliable remotely piloted aircraft (RPA) systems, radars, and electro-optic and related mission systems, including the Predator® RPA series and the Lynx® Multi-mode Radar. With more than eight million flight hours, GA-ASI provides long-endurance, mission-capable aircraft with integrated sensor and data link systems required to deliver persistent flight that enables situational awareness and rapid strike. The company also produces a variety of ground control stations and sensor control/image analysis software, offers pilot training and support services, and develops meta-material antennas. For more information, visit www.ga-asi.com.Avenger, Lynx, Predator, Reaper, SeaGuardian, and SkyGuardian are registered trademarks of General Atomics Aeronautical Systems, Inc.Contact InformationGA-ASI Media Relationsasi-mediarelations@ga-asi.comSource: General Atomics Aeronautical Systems, Inc. Copyright 2024 ACN Newswire via SeaPRwire.com.

HONG KONG, Dec 3, 2024 - (ACN Newswire via SeaPRwire.com) - December 2, 2024, In the context of the Belt and Road Initiative, the first Belt and Road Golden Route Series Financial Promotion Event——the Kyrgyz Republic Ministry of Finance's promotional seminar and non-deal roadshow was successfully held today in Hong Kong. The event was jointly hosted by TF International Securities Group Limited ("TF International") and China CITIC Bank International Limited ("China CITIC Bank International"), attracting numerous international investors and financial industry leaders.The Kyrgyz Republic, as one of the earliest countries to support and engage in the Belt and Road Initiative, has seen increasingly close economic and trade relations with China. Recently, TF International signed a memorandum of understanding with the Kyrgyz Republic Ministry of Finance, becoming the first Hong Kong-based Chinese securities firm to establish an official partnership with the Kyrgyz Republic Ministry of Finance. The two parties work together to promote the RMB internationalization, support the real economy, facilitate high-quality development, and reinforce Hong Kong’s position as an international financial center. The event featured distinguished guests, including Mr. Amanbaev Umutzhan Mominovich, Deputy Minister of Finance of Kyrgyz Republic, Mr. Abdybapov Abdanbek Abdybapovich, Head of the Government Borrowing Department of Kyrgyz Republic, Mr. CHAN Ho Lim, Joseph, JP, Under Secretary for Financial Services and the Treasury of Hong Kong S.A.R., and Mr. ZOU Chuan, CEO of TF International, as well as Mr. Andy Siow, Senior Coverage Banker, DCM, at China CITIC Bank International. They shared insights into Kyrgyzstan’s development opportunities and investment prospects in the international financial market, discussing investment opportunities and key focus areas for mutually beneficial cooperation. In his opening speech, Mr. CHAN Ho Lim, Under Secretary for Financial Services and the Treasury of Hong Kong, remarked, "Hong Kong has firmly established itself as Asia’s leading international financial centre. Our core strengths include free flow of capital and information, a robust common law system, and a simple and low tax regime, and Hong Kong enjoys preferential access to Mainland China. All these position Hong Kong as the super-connector between China and international markets, which plays a key role in promoting RMB internationalization and advancing the Belt and Road Initiative. The Kyrgyz Republic is an important partner under the Belt and Road Initiative and is certainly Hong Kong’s important trading partner in Central Asia.” He also stated that, “I would like to express my gratitude to the Kyrgyz Republic Ministry of Finance and TF International and appreciate your commitment to fostering stronger ties between Central Asia and Hong Kong. We look forward to exploring potential future collaborations with the Kyrgyz Republic that will benefit our respective markets and promote partnerships among Belt and Road nations.” As of September 1, 2024, Renminbi (RMB) has been included in the list of official daily exchange rates published by Kyrgyzstan, alongside the US dollar, euro, Russian ruble, and Kazakh tenge. This move further strengthens economic and financial cooperation between the two countries. Mr. Amanbaev Umutzhan Mominovich, Deputy Minister of Finance of the Kyrgyz Republic, stated, "The inclusion of the RMB in the list of official daily exchange rates in Kyrgyzstan marks a new stage in the economic cooperation between the two countries. This not only provides greater convenience for international investors but also empowers the development of Kyrgyzstan's financial market. Through this promotional event, we hope to connect with more international investment institutions and jointly promote the sustainable development of the regional economy." Hong Kong, as the international financial center and the central city of the Guangdong-Hong Kong-Macao Greater Bay Area, plays an important bridging role in the Belt and Road Initiative, leveraging its diverse financing channels and close alignment with national strategies. Mr. ZOU Chuan, CEO of TF International, stated, "The Belt and Road Initiative offers significant opportunities for economic integration and development, enhancing trade across Asia, Europe, the Middle East, and beyond. As a gateway between China and the world, Hong Kong is a key hub for the internationalization of the Renminbi, facilitating its use in trade and investment, and supporting effective currency risk management for BRI projects. With ongoing economic expansion and the internationalization of the Renminbi, Hong Kong is well-positioned to emerge as the premier financing hub. As we explore upcoming opportunities, I encourage you to envision the transformative impact these initiatives can have on the Kyrgyz Republic’s development agenda and the broader economic landscape of Central Asia. Together, we can unlock new avenues for growth and collaboration." From December 3 to 6, 2024, TF International, in collaboration with China CITIC Bank International will join forces with the Kyrgyz Republic Ministry of Finance in hosting a series of non-deal roadshows in Shanghai and Beijing, further strengthening ties with the Chinese financial market. The success of today’s promotional seminar and non-deal roadshow in Hong Kong marks a new milestone in the economic cooperation between the two countries and injects fresh momentum into the high-quality development of the Belt and Road Initiative. Copyright 2024 ACN Newswire via SeaPRwire.com.

London, UK, Dec 2, 2024 - (ACN Newswire via SeaPRwire.com) - The 3rd edition of the London Climate Technology Show concluded last week, paving a vital roadmap towards fully decarbonising our planet through sustainable technologies. The event brought together policymakers, eco-technology leaders, industry professionals, and innovators, all unified in their call for an immediate shift to sustainable and green solutions to secure a better future for the planet.The two-day event opened on 27th November with an inspiring keynote by Felicity Burch, Executive Director of the Responsible Technology Adoption Unit at the Department for Science, Innovation, and Technology (DSIT), who spoke about AI Innovation in Clean Energy and the DSIT's Manchester Prize. Following her, Ing. Abigail Cutajar, CEO of the Climate Action Authority, talked about Pioneering the Surge Towards Climate and Energy Transitions.The conference unfolded over two dynamic days, featuring a packed agenda of insightful presentations and engaging panel discussions. It delved into actionable strategies for decarbonisation, advancements in AgriTech, the evolving carbon market, eco-funds, energy, CCS, built environment and other groundbreaking innovations in climate technology.Notable discussions highlighted the need for farmers to balance carbon stewardship with food production over the next few decades, the importance of consistent government policies to enable businesses to plan and innovate effectively, and the urgency of addressing digital and engineering skill shortages to ensure a successful green energy transition. Industry experts also called for common sustainability metrics to measure corporate efforts fairly, emphasized the value of collaboration over competition to accelerate the green transition, and underscored the need for farmers to access landscape-level data to enhance biodiversity.The exhibition hall featured groundbreaking innovations and solutions in sustainability and climate technology, including carbon capture and storage (CCS) from companies like CGI and Terra CO2 Technology, carbon management and accounting solutions by Greenly and Gaia Carbon Accounting, and emerging climate technologies from innovators such as Nabla Flow and Luna 9. Other exhibitors showcased AI-driven solutions, sustainable energy systems, and innovative carbon reduction technologies, presenting a comprehensive snapshot of the future of climate tech.#CTS24 also hosted interactive side events, including startup acceleration programs and hands-on workshops, providing participants with opportunities for learning, networking, and collaboration. These sessions empowered attendees to adopt transformative technologies and take decisive climate action.Attendee ExperiencesThe event received overwhelming positive feedback:Mark Haley, Co-founder of Cero3, shared, "We’re so proud to have unveiled our sustainable travel planner. The feedback and interest exceeded our expectations."Satyajit Mohanan, Projects and Business Development Coordinator at Cambridge Cleantech, remarked, "It was a pleasure to be part of this event. I met amazing people and look forward to the next edition."Dennis Chacko, Senior Sales Manager at the British Board of Agreement, shared his excitement over a unique sustainable pen: "Once used, you can plant it to grow something new—a powerful reminder of how everyday items can contribute to a greener future."As this successful edition concludes, the organisers are already planning for a bigger, more impactful 4th Edition, with expanded content and greater opportunities to drive meaningful change toward a sustainable future.For further information, please reach out to us at press@valiantandcompany.com. Copyright 2024 ACN Newswire via SeaPRwire.com.

Key Financial Performance Highlights for Q1FY2025:Group’s total revenue for the quarter is RM40.2 million, contributed primarily by key clients in the e-mobility and energy storage segment, supplemented by the electronics segment.Recorded PAT of RM4.1million for the quarter under review.GP, PBT, PAT, and PATAMI margins remain in the double-digit levels at 18.2%, 10.9%, 10.2% and 11.9%, respectively due to continued cost discipline.BANGI, Malaysia, Nov 27, 2024 - (ACN Newswire via SeaPRwire.com) - Technology leader in providing turnkey, intelligent manufacturing automation solutions, GENETEC TECHNOLOGY BERHAD (“Genetec” or the “Company”), announced its financial results for the first quarter of its new financial year (“Q1FY2025). Despite the lower Year-on-Year (“YoY”) revenue, Genetec showcases its resilience with the continued profitability and high-double digit margins.The Company recorded revenue of RM40.2 million and gross profit (“GP”) of RM7.3 million for its Q1FY2025 ending 30 September 2024. It also reported profit before tax (“PBT”) of RM4.4 million, profit after tax (“PAT”) of RM4.1 million and profit after tax and minority interest (PATAMI) of RM4.8 million. Genetec continues to maintain double-digit margins for its GP, PBT, PAT and PATAMI of 18.2%, 10.9%, 10.2% and 11.9%, respectively.Genetec acknowledged that the last quarter has been challenging for the business which it believes was mainly attributed to policy uncertainties from the client’s operating markets. With the conclusion of the U.S. Presidential election and European policy developments, particularly on inflation, import tariffs, and decarbonisation, there is a sense of relief and clarity, and companies are moving forward with their capital expenditure with greater certainty.The Company, leveraging its expertise in customised automation technology and project execution, continue to work closely with its clients to deliver tailored solutions aimed at enhancing manufacturing automation, improving efficiency and increasing production yield for its clients. With its strong track record, Genetec is confident in its ability to continue to build trust and secure recurring business from its clients. Its high client retention rate stands as a testament to its exceptional performance and has been a key factor in the Company’s success. This strong foundation enables the Company to broaden its scope and product offerings with other divisions within the organisation of its existing clients to grow revenue over the long-term. At the same time, the Company’s business development team continue to explore new opportunities in new markets and industries, leveraging on its extensive experience and proven success working with leading international and reputable clients.Genetec’s Battery Energy Storage System (“BESS”) business is slowly gaining traction as it executes smaller-scale but strategically significant projects in both domestic and international markets. The Company remains confident that its execution capabilities and international track record will position Genetec favourably. Market developments such as the government’s recently announced Corporate Renewable Energy Supply Scheme (CRESS) through interest in pairing BESS technology with solar projects, will also support demand for BESS moving forward, and is a step in achieving 70 percent renewable energy in the capacity mix by 2050[1].Moving forward, Genetec remains committed to its strategy and focus on operational efficiency, strict cost management. With its low gearing levels and recent sale of subsidiary CLT Engineering Sdn Bhd to add to its already strong cash position, Genetec is positioning itself to ramp up operations in the coming months.About Genetec Technology BerhadGenetec Technology Berhad is a technology leader in providing customised full turnkey smart factory automation manufacturing lines. It is a public company listed on the Main Market of Bursa Malaysia Securities Berhad (Stock code: 0104). Its principal business focus is in the provision of high-quality, responsive and cost-effective designs, as well as the manufacturing of automated industrial systems, equipment and value-added services for its global customers in the Electric Vehicle (EV), Energy Storage, Automotive, Hard Disk Drive (HDD), Consumer Goods and Healthcare sectors.For more information please visit: https://genetec.net/.Issued by: Narro Communications on behalf of Genetec Technology Berhad[1] Source: Suruhanjaya Tenaga – Guidelines for CRESS Copyright 2024 ACN Newswire via SeaPRwire.com.

Vancouver, British Columbia--(ACN Newswire via SeaPRwire.com - November 28, 2024) - Military Metals Corp. (CSE: MILI) (OTCQB: MILIF) (FSE: QN90) (the "Company" or "MILI") is pleased to report that it has completed additional staking of claims surrounding the Last Chance antimony-gold property, located in Nye County, Nevada, just over 70km north of the town of Tonapah and 12km due west of Kinross' Round Mountain gold mine. The Company recently entered into a letter of intent to acquire the Last Chance antimony-gold property. Please refer to the Company's news release dated November 14, 2024, for additional details about the Last Chance property.Scott Eldridge, Chief Executive Officer of the Company, commented, "Antimony prices have now risen to $38,000 USD per tonne, making antimony the top performing commodity thus far for 2024. China's export restriction that came into play September 15, 2024, has created a supply crunch that has magnified the need for domestic development of defense sector metals. This additional staking solidifies complete coverage of what we believe is the entire mineralized system surrounding the Last Chance antimony-gold property."Location map, Last Chance PropertyTo view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/10818/231755_11f4bf32b4999b42_001full.jpgHistorical antimony-gold occurrences and a solitary shaft where limited historical production is recorded occur within a sequence of Paleozoic carbonates and Lower Mesozoic metamorphosed shales and carbonates; A series of ultramafic dykes as well as younger felsic intrusives and extrusives cut this sequence at several locations. Mineralization is structurally controlled, with folding, faulting and quartz veining seen throughout the metamorphosed sedimentary sequence at several locations across the property.A fence of claims was staked surrounding the Last Chance property to ensure that additional ground considered potentially prospective remains available to the Company when it begins its first field campaign scheduled for Q2/2025.The technical contents of this release were reviewed and approved by Avrom E. Howard, MSc, PGeo, geological consultant to Military Metals and a qualified person as defined by NI 43-101.About Military Metals Corp. The Company is a British Columbia-based mineral exploration company that is primarily engaged in the acquisition, exploration and development of mineral properties with a focus on antimony.ON BEHALF OF THE BOARD of DIRECTORSFor more information, please contact:Scott EldridgeCEO and Directorscott@militarymetalscorp.comFor enquiries, please call 604-722-5381 or 604-537-7556This news release contains "forward-looking information". Often, but not always, forward-looking statements can be identified by the use of words such as "plans", "expects", "is expected", "budget", "scheduled", "estimates", "forecasts", "intends", "anticipates", or "believes" or variations (including negative variations) of such words and phrases, or state that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved. Forward-Looking information in this news release includes statements related to the completion of a binding agreement and closing of the acquisition of the Last Chance Gold Property, as well as future plans for exploration activities, and assumptions related to the continuation of the global demand for antimony. A variety of factors, including known and unknown risks, many of which are beyond our control, could cause actual results to differ materially from the forward-looking information in this news release. These include meeting the conditions to close the acquisition of the Last Chance Gold Property, geopolitical developments related to the supply of antimony, the continued use of antimony and availability of alternatives, availability of capital and labour in respect of the properties that are the subjects of this news release, the results of any future exploration activities, which cannot be guaranteed, and such other factors as may impact both and any future activities in respect of the properties. Additional risk factors can also be found in the Company's public filings under the Company's SEDAR+ profile at www.sedarplus.ca. Forward-Looking statements contained herein are made as of the date of this news release and the Company disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events or results or otherwise. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. The Company undertakes no obligation to update forward looking statements if circumstances, management's estimates or opinions should change, except as required by securities legislation. Accordingly, the reader is cautioned not to place undue reliance on forward-looking statements.The Canadian Securities Exchange has neither approved nor disapproved the information contained herein and does not accept responsibility for the adequacy or accuracy of this news release.To view the source version of this press release, please visit https://www.newsfilecorp.com/release/231755 Copyright 2024 ACN Newswire via SeaPRwire.com.

SHANGHAI, Nov 30, 2024 - (ACN Newswire via SeaPRwire.com) - Hua Medicine (the “Company”, HKEx stock code: 2552) announced today that the Company has successfully completed a Phase I clinical trial on its 2nd generation GKA candidate in U.S. at the 9th China BioMed Innovation and Investment Conference (CBIIC).The Phase Ia clinical trial of the second-generation GKA (HM-002-1005) was conducted in the United States in 40 subjects with Type 2 diabetes (T2D). This trial was randomized, double-blind, placebo-controlled, single-dose, focusing on safety, tolerability, and pharmacokinetics. The second-generation GKA is a novel molecular entity with optimized physicochemical properties, holding new patents, and serving as the prodrug of dorzagliatin (HMS5552). This study designed for once-daily oral administration. Its aim is to extend the drug's action duration in the body through sustained-release technology, enhance patient compliance, and prolong the stimulation of GLP-1 secretion in the intestines.The Single Ascending Dose (SAD) study demonstrates that HM-002-1005 tablets can be rapidly converted to HMS5552 in the human body, with minimal exposure level of prodrug in both blood and urine. The t1/2 (biological half-life) after a single dose of HM-002-1005 tablets was prolonged compared to dorzagliatin tablets. The Cmax of HMS5552 in plasma after a 184.5mg single dose is comparable to the plasma concentration of HMS5552 after a 75mg single dose of dorzagliatin tablet; likewise, the daily AUC of HMS5552 in plasma after a single dose of HM-002-1005 tablets is comparable to the exposure level of HMS5552 after a 75mg BID dose of dorzagliatin tablets. The research indicates that HM-002-1005 tablets are near-completely converted to HMS5552 in human, and its pharmacokinetic characteristics support for once-daily oral administration. The development of HM-002-1005 tablets not only contributes to enhancing patient medication adherence and effectively control blood glucose levels within 24 hours; meanwhile, it also offers the opportunity to explore the Maximum Tolerated Dose above 150mg daily to achieve better efficacy. The 75 mg BID dose regiment was developed under the concept of Minimum Therapeutic Effective Dose in Chinese T2D patients who suffered from an impairment of insulin secretion and significant reduction of early phase insulin. The different disease characters of T2D with obesity in western patient population would benefit dorzagliatin from its effects on GLP-1 secretion and improvement of insulin sensitivity.With the confirmation that the exposure level of HM-002-1005 tablets at 184.5mg is comparable to dorzagliatin tablets at 75mg (BID), we will further optimize the dosage form followed by a Multiple Ascending Dose (MAD) clinical development of the 2nd generation GKA in China and the United States.Dr. Li CHEN, founder and CEO of Hua Medicine, stated, “Hua Medicine has always been committed to treating Type 2 diabetes at its root cause by restoring patients’ ability to autonomously regulate blood glucose levels. Over the course of a decade, the Company has selected dosing and clinical research protocols that are safe and effective for the majority of Chinese diabetes patients, leading to the successful development of GKA and the clinical application of dorzagliatin. Building on this foundation, the Company will undergo a strategic upgrade by further exploring the therapeutic potential of GKA, enriching its product pipeline and seeking partners both domestically and internationally, in order to benefit a broader range of patients, expand into global markets, and effectively establish the brand identity of GKA medications while maximizing the commercial potential of our global first-in-class drugs.”About Hua MedicineHua Medicine (The “Company”) is an innovative drug development and commercialization company based in Shanghai, China, with companies in the United States and Hong Kong. Hua Medicine focuses on developing novel therapies for patients with unmet medical needs worldwide. Based on global resources, Hua Medicine teams up with global high-calibre people to develop breakthrough technologies and products, which contribute to innovation in diabetes care. Hua Medicine's cornerstone product HuaTangNing (Dorzagliatin tablets), targets the glucose sensor glucokinase, restores glucose sensitivity in T2D patients, and stabilizes imbalances in blood glucose levels in patients. HuaTangNing was approved by the National Medical Products Administration (NMPA) of China on September 30th, 2022. It can be used alone or in combination with metformin for adult T2D patients. For patients with chronic kidney disease (CKD), no dose adjustment is required. It is an oral hypoglycemic drug that can be used for patients with Type 2 diabetes with renal function impairment.For more informationHua MedicineWebsite: www.huamedicine.comInvestorsE-mail: ir@huamedicine.comMediaE-mail: pr@huamedicine.com Copyright 2024 ACN Newswire via SeaPRwire.com.

SHANGHAI, Nov 30, 2024 - (ACN Newswire via SeaPRwire.com) - Hua Medicine (the “Company”, HKEx stock code: 2552) announced today that the Company has successfully completed its SENSITIZE study on the mechanism by which dorzagliatin improves the β-cell glucose sensitivity at the 9th China BioMed Innovation and Investment Conference (CBIIC).The SENSITIZE study was initiated by Professor Juliana Chan, an international endocrinology specialist at The Chinese University of Hong Kong, as the lead researcher. It is the first clinical study in Asian populations to evaluate the impact of GKA on β-cell glucose sensitivity in the populations with varying degrees of impaired glucose tolerance using the technology of hyperglycemic clamp. The study aims to explore the impairment of glucokinase (GK) function and clinical characteristics in different types of glucose dysregulation, providing new scientific evidence on the pathophysiology of Asian Type 2 diabetes and the central role of GK in blood glucose regulation.The SENSITIZE 2 study results announced at CBIIC demonstrate that a single dose of dorzagliatin restores GK enzyme activity, significantly improving the second-phase insulin secretion and β-cell glucose sensitivity in individuals with impaired glucose tolerance (IGT) in hyperglycemic clamp study. In addition, the SENSITIZE 1 study previously reported at the 2022 ADA annual meeting showed that dorzagliatin directly restores the activity of GK mutants, leading to significant improvements in the second-phase insulin secretion and β-cell glucose sensitivity in patients with glucokinase monogenic diabetes (GCK-MODY or MODY-2), and significantly enhance basal insulin secretion in newly diagnosed type 2 diabetes patients.Hua Medicine will continue to investigate β-cell glucose sensitivity improvement and incretin effect in response of repeated dose of dorzagliatin in individuals with intermediate hyperglycemia (IH) and Type 2 diabetes, in order to establish personalized intervention and treatment management plans for prediabetic and Type 2 diabetes patients.About Hua MedicineHua Medicine (The “Company”) is an innovative drug development and commercialization company based in Shanghai, China, with companies in the United States and Hong Kong. Hua Medicine focuses on developing novel therapies for patients with unmet medical needs worldwide. Based on global resources, Hua Medicine teams up with global high-calibre people to develop breakthrough technologies and products, which contribute to innovation in diabetes care. Hua Medicine's cornerstone product HuaTangNing (Dorzagliatin tablets), targets the glucose sensor glucokinase, restores glucose sensitivity in T2D patients, and stabilizes imbalances in blood glucose levels in patients. HuaTangNing was approved by the National Medical Products Administration (NMPA) of China on September 30th, 2022. It can be used alone or in combination with metformin for adult T2D patients. For patients with chronic kidney disease (CKD), no dose adjustment is required. It is an oral hypoglycemic drug that can be used for patients with Type 2 diabetes with renal function impairment.For more informationHua MedicineWebsite: www.huamedicine.comInvestorsE-mail: ir@huamedicine.comMediaE-mail: pr@huamedicine.com Copyright 2024 ACN Newswire via SeaPRwire.com.

Highlights (relevant audited data for the year ended 31 August 2024)- Revenue increased by 17% YoY to approximately RMB2,312 million;- Gross profit rose by 10% YoY to approximately RMB1,124 million;- Profit for the period attributable to owners of the Company rose by 16% YoY to approximately RMB715 million;- Number of student enrolments increased by 11% YoY to approximately 95,600;- Payment of a final dividend of HK10.0 cents per share;- Dividend payout ratio of 30% for the year.HONG KONG, Nov 29, 2024 - (ACN Newswire via SeaPRwire.com) - Edvantage Group Holdings Limited (“Edvantage Group” or the “Group”, stock code: 0382.HK) has announced its audited FY2024 Annual Results for the year ended 31 August 2024 (the “Reporting Period”). During the Reporting Period, the Group actively responded to national policies, vigorously promoted industry-education integration, deepened the connotations of international education, continued to introduce unique new featured majors that match market and industry demands and fully embraced artificial intelligence (“AI”), succeeding in raising education quality and brand presence, thereby achieving steady growth in performance year after year.During the Reporting Period, the Group’s revenue totaled approximately RMB2,312 million, representing an increase of 17% as compared to the corresponding period of the preceding year. The increase was mainly attributable to the continuous enhancement of the Group’s education brand effectiveness, which drove a rise in the number of student enrolments and higher average tuition fees recorded by the Group’s domestic schools. Profit for the period attributable to owners of the Company rose by 16% YoY to approximately RMB715 million. The number of students enrolled in the Group’s schools continued to expand yearly, reaching approximately 95,600, with a year-on-year growth of approximately 11%. The Board of Directors of the Group has recommended the payment of a final dividend of HK10.0 cents per share for the year ended 31 August 2024, which, along with an interim dividend of HK9.6 cents per share, equates to a total annual dividend of HK19.6 cents per share and a dividend payout ratio of 30% for the year.From left to right: Mr. Yan Kwok Ting Sunny, Director of Investment, Corporate Finance & Investor Relations Department;Mr. Liu Yuk Tung, ChiefFinancial Officer; Ms. Liu Yi Man, Executive Director and Chief Executive Officer;Ms. Liu Wenqi, Chief Operating Officer;Fully embracing AI and continuously promoting the industry-education integrationOver the past year, the Group witnessed the groundbreaking development of the new generation of artificial intelligence technology. As a vocational education provider, the Group has developed in step with times, fully embracing AI in teaching, management and application. At present, all of its schools are actively promoting AI, fostering its popularity, with AI-embedded courses launched in seven colleges. Subsequent efforts will be made to promote those programmes to cover all faculties and students of all schools under the Group. Meanwhile, the Group actively responded to national policies, continuously deepened industry-education integration, and fully promoted the construction of industrial colleges, cooperating with multiple enterprises renowned in their respective industries to establish artificial intelligence and big data, digital trade, digitalised accounting and business services, research and tourism, jewelry, human resources and other industrial colleges. Those industrial colleges are all set up according to the Ministry of Education requirements for building modern industrial colleges that align with the country’s key industry development strategies, in order to nurture high-quality application-minded talent that emerging industries urgently need. In addition, the Group also entered into school-enterprise cooperation with numerous enterprises to build off-campus practice bases, further promoting the in-depth integration of education chains and industrial chains.Expanding exchange and cooperation of international education and deepening the connotations of international educationThe Group responded to the national advocacy for the opening up of education, “introduction of foreign schools”, and “international expansion of domestic schools”, continuously promoted the internationalisation of vocational education and expanded the partnership network with global renowned universities. By providing high-quality international programs and practice opportunities to students, the Group aims to cultivate innovative talents with global vision, to further raise the international influence of China’s vocational education. During the Reporting Period, the schools under the Group established in-depth cooperation with 51 foreign high schools in the United States of America, the United Kingdom, Canada, Japan and Australia, joining hands to create diverse high-quality international programmes. Furthermore, the Group comprehensively launched international study tours, organising 65 student and teacher study tours to France, Singapore, Hong Kong, China, Macau, China and other regions for short-term studies, with over 4,000 teachers and students participating during the Reporting Period. Looking forward, the Group will press on with deepening integration of its schools - domestic and international, strive to build a diversified international education cooperation network, actively promote Chinese vocational education to go global and build an internationally renowned Chinese vocational education brand.Consistently increasing investment in education to build a high-quality education brandThe Group has always adhered to the motto of "Establishing school of the century, Nurturing talents of the nation". Firmly believing that increasing investment in education is an important path towards high-quality education, the Group further expanded the new campus of Guangzhou Huashang College and Guangzhou Huashang Vocational College during the Reporting Period, which includes student dormitories, library, sports centre, teaching buildings and laboratories, providing solid support for future student enrollment and sustainable development of the Group. At the same time, it has kept increasing investment in building a high-quality teaching staff, which has expanded after the Guangzhou Huashang College and Guangzhou Huashang Vocational College established their Guangdong Province Doctoral Workstation respectively. The Group has launched a series of training workshops for teachers to continuously enhance their professionalism and practical teaching abilities, encouraging them to practice what they have learned and help improve school education and teaching quality. By introducing mentors from industries, it works together with enterprises in nurturing professional “dual-qualified” teachers and “dual-skilled” industry mentors, continuing to optimize the combined structure of full-time and part-time faculty teams. The in-depth and precise investment made by the Group in various areas crucial to strengthening school management has brought bountiful results. Guangzhou Huashang College placed third in scientific research competitiveness among private undergraduate colleges in China and has been designated as a key research base for humanities and social sciences among regular higher education institutions in Guangdong Province. Guangzhou Huashang Vocational College has been named a national exemplary vocational college, while the Urban Vocational College of Sichuan ranked second in China and first in Sichuan among Shanghai Ranking's 2024 Best Chinese Private Higher Vocational Colleges. These honors are a strong testament to the Group’s high-quality educational achievements.Looking ahead, the Group will continue to nurture innovative talent, focusing on such areas as industry and education integration, internationalization, and AI to keep up with industry and social development needs, increase investment in education, and keep building a high-quality education brand. It is committed to nurturing highly-skilled interdisciplinary corporate leaders for the country and industries around the world, while continuously making positive contributions to the sustainable development of vocational education.About Edvantage Group Holdings LimitedEdvantage Group Holdings Limited (“Edvantage Group” or the “Group”, stock code: 0382.HK) is the largest private business higher education and vocational education group in the Greater Bay Area, and an early mover in education sector in pursuing international expansion, listed in Hong Kong Main Board on 16 July 2019. The total number of full-time student enrolments of the Group was approximately 96,000 as of 31 August 2024. Operated 9 private education institutions, namely, Guangzhou Huashang College (Applied Undergraduate), Guangzhou Huashang Vocational College (Higher Vocational Education) and Guangdong Huashang Technical School (Secondary Vocational Education) located in Guangdong Province, the PRC; Urban Vocational College of Sichuan (Higher Vocational Education) and Urban Technician College of Sichuan (Secondary Vocational Education) in Sichuan Province, the PRC; GBA Business School (GBABS) in Hong Kong, the PRC; Global Business College of Australia (GBCA) and Edvantage Institute Australia (EIA) in Australia; as well as Edvantage Institute (Singapore) (EIS) in the downtown of Singapore.While focusing on school operations, the Group also actively fulfil corporate social responsibility, extensively contributing to social welfare programmes including charity, poverty alleviation, education and revitalisation, in order to take the initiative in repaying society through action. Since its listing, the Group has made outstanding contributions in the field of ESG and has won the “Best ESG Innovation Award” from Zhitong Finance and the “Outstanding Enterprise for ESG Innovative Practice” from Gelonghui in 2024. Copyright 2024 ACN Newswire via SeaPRwire.com.

HONG KONG, Nov 29, 2024 - (ACN Newswire via SeaPRwire.com) - The Hong Kong Institute of Directors ("HKIoD") announced the winners of its Award Series for Director Excellence (the "Awards") – comprising the long-established Directors of the Year Awards ("DYA") and the inaugural Climate Governance Awards ("CGA"), at its Annual Dinner yesterday at the Hong Kong Convention and Exhibition Centre. The event began with an opening speech by Dr Christopher To, Chairman of the HKIoD. Dr The Hon Moses Cheng Mo Chi, Non-official Member of the Executive Council of HKSARG, Mr Xu Wei Gang, Director General, Department of Economic Affairs, Liaison Office of the Central People's Government in HKSAR, Ms Salina Yan, JP, Permanent Secretary for Financial Services and the Treasury (Financial Services), and Dr Kelvin Wong, Chairman, Securities and Futures Commission ("SFC") and Chairman, Accounting and Financial Reporting Council ("AFRC") were invited as guests of honour. The response to the Awards submissions was overwhelmingly positive. After a lively discussion among the judges, this year's 19 winners, including directors and boards, were selected - all embodying the theme "Leading with Agility in an Era of Innovation". The awardees have demonstrated not only agility, but also the vision, courage and wisdom to lead against the backdrop of a demanding economic environment and prevailing geopolitical tensions. Moreover, they highlight the importance of having directors who can guide their companies in identifying the risks and opportunities associated with climate change, which are vital for ensuring the sustainability of the world and humanity.The Awardees of HKIoD Award Series* for Director Excellence 2024 are listed below:*Two series of Awards:- "DYA", acronym for "Directors Of The Year Awards"- "CGA", acronym for "Climate Governance Awards"In alphabetical order of names within categoryListed Companies CategoriesExecutive DirectorsDYAMr Chan Wai MingTown Ray Holdings LimitedCGAMs Clara Chan Yuen-shanLee Kee Holdings LimitedDYAMr Fu FanChina Pacific Insurance (Group) Co., LtdCGA Mr Li Wai LeungHengan Internationals Group Company LimitedMr Peter Wong Wai-YeeThe Hong Kong and China Gas Company LimitedDYA & CGAMr Yan Jianguo JPChina Overseas Land & Investment LimitedNon-Executive DirectorsDYA Dr Chung Shui Ming TimpsonChina Railway Group LimitedDr Tseng Shieng-chang CarterTCL Electronics Holdings LimitedProf Wang YijiangTCL Electronics Holdings LimitedBoardsDYA & CGAChina Resources Beer (Holdings) Company LimitedCGAHong Kong and China Gas Company LimitedDYA & CGAPing An Insurance (Group)Company of China, LtdCGAUnited Company RUSAL, international public joint-stock companyNon-listed Companies CategoriesExecutive DirectorsDYAMs Michelle ChanAS Watson IndustriesCGA Ir Prof Daniel M.ChengDunwell Technology (Holdings) Limited) (Dunwell Group)Ir Dr Cheng Sai Yau, VincentArup Fellow and Director of Climate and Sustainability in East AsiaDYAMr Orr Ka-yeung KevinWinner Medical (Hong Kong) LtdStatutory/ Non-profit-distributing Organisations CategoriesBoardsDYAHong Kong Tourism Board*In addition: recognition of Excellence in Board DiversityThe Institute of Internal Auditors Hong Kong*In addition: recognition of Excellence in Board DiversityThe guests of honour, special guests and officials to join the group photos together with the awardees (2nd row).About "HKIoD Award Series for Director Excellence"The HKIoD Award Series for Director Excellence is a project organised by The Hong Kong Institute of Directors ("HKIoD") and consists of two series of Awards.The first series, Directors Of The Year Awards, was inaugurated in 2001 as the first ever such Awards organised in Asia. As directors are ultimately responsible for corporate governance and leading the company in prosperity and integrity, the objectives of the Awards are to recognise outstanding boards and directors and to promote good practices in corporate governance and director professionalism. The Awards have become an annual project of impact in the community organised by HKIoD together with over 100 Project Partners. To date, 255 Awardees have been recognised for their achievements in demonstrating exemplary high standards in corporate governance and director practice.Inaugurated in 2024, Climate Governance Awards constitute the second series of HKIoD Awards with the objectives to recognise and inspire exemplary achievements in climate governance and to advocate climate action by directors. There are 10 awardees who have been acknowledged in the inaugural edition of the awards. It is critical time now for directors to address the risks and opportunities of climate change in board agendas and their governance role.Candidates are open to public nomination, with data processed in well-defined and stringent procedures, followed by interviews with independent consultants in utmost due diligence and finally selected by independent judges with high standards and fair judgment. Awards are presented by company categories, viz Listed Companies, Non-listed Companies and Statutory/Non-profit-distributing Organisations, and by capacities, viz Executive Directors, Non-Executive Directors and Boards.About The Hong Kong Institute of Directors ("HKIoD")The Hong Kong Institute of Directors ("HKIoD") is Hong Kong's premier body representing directors working together to advance corporate sustainability in creating long-term value for companies, their owners, stakeholders, humankind and Planet Earth through advocacy and standards-setting in corporate governance and director professionalism. Led by Founder Chairman Dr The Hon Moses Cheng, HKIoD was founded in 1997. Throughout the years, HKIoD is honoured to have the Chief Executive of HKSAR as the Institute's Patron. Membership of HKIoD comprises of directors from diverse industries and corporate types and includes Executive Directors, Non-Executive Directors and Independent Non-Executive Directors. With multi-culturalism and international perspectives, HKIoD organises activities that cover director training, seminars and forums, collective director voice, guideline establishment, public education, Award Series for Director Excellence, assessment of Corporate Governance Scorecard for listed companies etc.As a member body of the Global Network of Director Institutes ("GNDI"), HKIoD is committed to global collaboration in promoting good corporate governance and director professionalism. HKIoD is the appointed Host of the Hong Kong Chapter of Climate Governance Initiative, a global network that collaborates with the World Economic Forum in actively promoting directors' address of the risks and opportunities of climate change.For details please visit:http://www.hkiod.com|http://www.gndi.org|https://climate-governance.org/Media Enquiries:Award Series for Director Excellence:Strategic Public Relations Group LimitedThe Hong Kong Institute of DirectorsBrenda Chan+852 2114 4396/ brenda.chan@sprg.com.hkOdessa So +852 2889 4988/ odessa.so@hkiod.com Copyright 2024 ACN Newswire via SeaPRwire.com.

SAN FRANCISCO, CA & MUMBAI, Nov 28, 2024 - (ACN Newswire via SeaPRwire.com) - Niyo, India’s leading fintech startup, teamed up with CleverTap, the all-in-one engagement platform, to improve customer experiences through personalized engagement and real-time interactions. Since its founding in 2015, Niyo has been revolutionizing financial services in India, particularly with its international travel cards and app-based financial services, catering to the evolving needs of its users.In its almost decade-long journey, Niyo recognized the challenges that modern Indian travellers face at every touchpoint while venturing abroad. It sought a feature-rich user engagement platform that would effectively deliver the right solutions to its customers and found the ideal partner in CleverTap. By leveraging CleverTap’s advanced automation tools, Niyo enhanced its onboarding processes, while ensuring compliance with regulations, and streamlining customer experiences. This collaboration empowered Niyo to reduce drop-offs during the customer journey, automate personalized messages, and re-engage dormant users.By deploying CleverTap’s integrated platform, Niyo achieved:・2x increase in click through rates, leveraging Clever.AI for emotionally intelligent content.・40% optimized conversion rate through pinpoint targeting, ensuring personalized and relevant communication at every step.・12% re-engagement of dormant users through targeted campaigns, highlighting Niyo’s success in winning back inactive customers.Sushanth Ravikumar, SVP - Head of Marketing, Niyo, said - “At Niyo, delivering a seamless and personalized experience for our customers is a top priority. CleverTap has been instrumental in elevating this experience. Its robust automation and communication tools have streamlined our onboarding process while maintaining compliance in the highly regulated sector. What started as a tool to streamline everyday operations has become a key force in helping us preserve customer trust, even during challenging times. Its ability to adapt to real-time shifts in customer engagement offers us a definitive edge in an ever-changing dynamic, solidifying our long-term confidence in the platform.”Sidharth Pisharoti, Chief Revenue Officer, CleverTap, said - “We are excited to collaborate with Niyo as they continue to innovate in the travel fintech space. Through our partnership, we’ve been able to enhance Niyo’s customer engagement by focusing on delivering personalized and timely experiences. This has not only streamlined their processes but also improved customer satisfaction, particularly in key areas like onboarding and transaction management. We look forward to supporting Niyo as they scale and evolve their offerings in this dynamic market.”About Niyo Niyo is India’s leading banking fintech that has revolutionized "travel banking" for Indians. The company was co-founded by banking veteran Vinay Bagri (currently, CEO) and technology veteran Virender Bisht (currently, CTO) in 2015. Niyo offers zero forex debit and credit cards, which provides the best banking experience and value for international travellers. This unique solution was invented by Niyo in 2015 and has helped over 2 million Indians by saving more up to 5% on their international transactions with Zero Forex offering. In this last Series-C round in 2022, Niyo raised $130 million, which was led by global VC and PE firms, Accel, Lightrock, and Multiples. Its other investors include Prime Venture Partners, Horizons Ventures, Tencent, JS Capital, Social Capital, and Beams Fintech Fund. Niyo operates out of a corporate office in Bengaluru and has a sales presence in more than 20 states and union territories.Visit: GoNiyo.comAbout CleverTapCleverTap is the leading all-in-one customer engagement platform that helps brands unlock limitless customer lifetime value. CleverTap is trusted by over 2000 brands like Decathlon, Domino’s, Levis, Jio, Emirates NBD, Puma, Croma (A Tata Enterprise), Swiggy, SonyLIV, Axis Bank, AirAsia, TD Bank, Ooredoo, and Tesco, to help build personalized experiences for all their customers. The platform is powered by TesseractDB™ – the world’s first purpose-built database for customer engagement, offering speed and cost efficiency at scale.Backed by top-tier investors such as Accel, Peak XV Partners, Tiger Global, CDPQ and 360 One, the company is headquartered in San Francisco, with presence across Seattle, London, São Paulo, Bogota, Mexico, Amsterdam, Sofia, Dubai, Mumbai, Bangalore, Singapore, Vietnam, and Jakarta.For more information, visit CleverTap.com or follow us on:LinkedIn: https://www.linkedin.com/company/clevertap/ X: https://twitter.com/CleverTap Forward-Looking StatementsSome of the statements in this press release may represent CleverTap's belief in connection with future events and may be forward-looking statements, or statements of future expectations based on currently available information. CleverTap cautions that such statements are naturally subject to risks and uncertainties that could result in the actual outcome being absolutely different from the results anticipated by the statements mentioned in the press release.Factors such as the development of general economic conditions affecting our business, future market conditions, our ability to maintain cost advantages, uncertainty with respect to earnings, corporate actions, client concentration, reduced demand, liability or damages in our service contracts, unusual catastrophic loss events, war, political instability, changes in government policies or laws, legal restrictions impacting our business, impact of pandemic, epidemic, any natural calamity and other factors that are naturally beyond our control, changes in the capital markets and other circumstances may cause the actual events or results to be materially different, from those anticipated by such statements. CleverTap does not make any representation or warranty, express or implied, as to the accuracy, completeness, or updated or revised status of such statements. Therefore, in no case whatsoever will CleverTap and its affiliate companies be liable to anyone for any decision made or action taken in conjunction.For more information:SONY SHETTYDirector, Communications and CSR, CleverTap+91 9820900036sony@clevertap.com ASHMIT CHAUDHARYAssociate Consultant, Archetype+91 8850752121ashmit.chaudhary@archetype.co Copyright 2024 ACN Newswire via SeaPRwire.com.

HONG KONG, Nov 28, 2024 - (ACN Newswire via SeaPRwire.com) - China’s largest retail digitalization solution provider – Dmall Inc. (“Dmall” or the “Company”, Stock Code: 02586.HK), today announced the proposed listing of its shares on the Main Board of The Stock Exchange of Hong Kong Limited (“Hong Kong Stock Exchange”).Dmall plans to offer 25,774,000 Shares (subject to the over-allotment option), of which 23,196,600 Shares will be International Offer Shares (subject to reallocation and the over-allotment option), representing approximately 90% of the initial offer shares; the remaining 2,577,400 Shares will be Hong Kong Offer Shares (subject to reallocation), representing approximately 10% of the initial offer shares. The Offer Price is HK$30.21 per Share, plus brokerage of 1.0%, SFC transaction levy of 0.0027%, Hong Kong Stock Exchange trading fee of 0.00565% and Accounting and Financial Reporting Council transaction levy of 0.00015% (payable in full on application in Hong Kong dollars and subject to refund).Dmall will open for Hong Kong Public Offering in Hong Kong at 9 a.m., November 28, 2024 (Thursday), and close at 11:30 a.m., December 3, 2024 (Tuesday). Dealings in shares of Dmall on the Main Board of the Hong Kong Stock Exchange is expected to commence on December 6, 2024 (Friday). The shares will be traded in board lot of 100 shares each. The Company’s stock code will be 02586.HK.UBS Securities Hong Kong Limited, CMB International Capital Limited and China Merchants Securities (HK) Co., Limited are the Joint Sponsors. UBS AG Hong Kong Branch, CMB International Capital Limited, China Merchants Securities (HK) Co., Limited, CLSA Limited and China International Capital Corporation Hong Kong Securities Limited are the Joint Global Coordinators, Overall Coordinators, Joint Bookrunners and Joint Lead Managers.After deducting the underwriting commissions and other estimated offering expenses payable by the Company, with an Offer Price of HK$30.21 per Offer Share, the Company estimates that it will receive net proceeds of approximately HK$623.7 million from the Global Offering after deducting the underwriting commissions and fees, and other estimated expenses in connection with the Global Offering and assuming that the Over-allotment Option is not exercised. In line with Dmall’s strategies, the proceeds from the Global Offering are intended to be used for the following purposes and in the following amounts – approximately 42.1%, or HK$262.6 million, to develop new applications and new service modules; approximately 30.0%, or HK$187.1 million, for talent acquisition associated with the expansion of Dmall’s operations; approximately 10.0%, or HK$62.4 million, to selectively pursue strategic cooperation, investments and acquisitions that are complementary to its organic growth strategies, particularly those that can complement Dmall’s product offerings, strengthen its technology capabilities, and solidify its market position; approximately 7.9%, or HK$49.3 million, to expand its sales network and further strengthen its brand reputation; and approximately 10.0%, or HK$62.4 million, for working capital and general corporate purposes.Dmall was founded in 2015, which provides retail digitalization solutions to retailers in the local retail industry. According to Frost & Sullivan, Dmall is the largest retail cloud solution provider in China by GMV, with a market share of 13.3% in 2023. The expansion has allowed the Company to become the largest retail cloud solution provider in Asia by GMV in 2023, occupied a market share of 10.9%, according to Frost & Sullivan.As a leading retail digitalization solution provider in Asia, the broadest operational modules coverage enables Dmall to cover diverse customer base in the retail industry and thus obtain deep retail know-how, meet the needs of all major aspects of the retailer's operations. Dmall served 444 customers in the six months ended June 30, 2024, such as Pangdonglai, Luosen (China), Dennis and Maidelong Entities, as well as well-known brands such as Wellcome, Mannings, Guardian, Giant and 7-Eleven (Hong Kong), which operate under the DFI Retail Group, demonstrating a widely validated operating model. The dollar-based net retention ratio was 184% in 2021, 158% in 2022, 117% in 2023 and 123% in the twelve months ended June 30, 2024, remaining robust at above 100%, which underscores Dmall’s ability to further increase customer spending.Dmall has always attached importance to the value created for customers, “customer success” is the starting point of everything the Company does. Dmall has provided services to leading companies in different retail formats, and has successfully expanded its businesses markets outside of the Chinese mainland, comprising Hong Kong SAR, Cambodia, Singapore, Malaysia, Poland, Macau SAR, Indonesia, the Philippines and Brunei. In terms of income, the overseas income of the Company in 2023 has exceeded RMB100 million.Dmall achieved strong revenue growth as its revenue grew by 56.6% from RMB848.2 million in 2021 to RMB1,328.3 million in 2022, and further increased by 19.4% to RMB1,585.4 million in 2023. Dmall’s revenue increased by 22.9% from RMB764.0 million in the six months ended June 30, 2023 to RMB939.2 million in the six months ended June 30, 2024. Dmall has also improved its gross margin during the Track Record Period. Dmall’s gross margins were 20.4%, 38.0%, 35.0%, 36.3% and 38.3% in the years ended December 31, 2021, 2022, 2023 and the six months ended June 30, 2023 and 2024, respectively.Mr. Zhang Feng, co-founder, executive Director and president of Dmall said, “We empower retailers to thrive in the digital era and are committed to becoming the world's leading omnichannel retail digital solutions provider. We will uphold the values of "continuous innovation", always strive, constantly strengthen and uphold our own technical barriers and optimize products and services, maintain core competitiveness, continue to provide customers with high-value services, and help customers' business. We look forward to taking the listing as an opportunity to fully leverage our competitive advantages and utilize Hong Kong's unique financing platform to further enhance our strengths and continue to create greater value for our shareholders and investors.”Issued by Porda Havas International Finance Communications Group for and on behalf of Dmall Inc. For further information, please contact:Porda Havas International Finance Communications GroupMS.Fung Kelly(852) 3150 6763kelly.fung@h-advisors.globalMS.Wang Evie(86) 135 2006 8960evie.wang@h-advisors.global Copyright 2024 ACN Newswire via SeaPRwire.com.

DUBAI, UAE, Nov 28, 2024 - (ACN Newswire via SeaPRwire.com) - Since its inception in 2017, the World Blockchain Summit (WBS) has grown into the world’s longest-running and most prestigious blockchain and Web3 event series, hosting 29 successful editions across 16 countries. Over the years, WBS has established itself as a key platform that unites global innovators, investors, and policymakers to shape the future of decentralised technology. Today, Trescon proudly announces the evolution of this iconic event with a bold rebranding to HODL, a name that embodies resilience, progress, and the limitless potential of blockchain and Web3 ecosystems.HODL will make its highly anticipated debut at the 30th global edition of the summit in Dubai, UAE, on April 28-29, 2025. This rebranding marks a significant shift toward positioning the event as a premier platform for serious business, innovation, and deal-making in the blockchain space.Why the RebrandThe transition from WBS to HODL reflects the evolution of the event from a conference series to a strategic platform driving real business outcomes. HODL now embraces not only blockchain but also the broader horizons of innovation and collaboration within Web3, crypto, and emerging decentralised systems. The focus is on creating meaningful connections between ground-breaking blockchain projects, pre-qualified investors, enterprise leaders, and government regulators. This shift reflects a commitment to facilitating collaborations that will shape the future of the blockchain industry.What to Expect at HODL 2025 in DubaiTrailblazing Thought Leaders: Hear from top blockchain innovators, industry pioneers, and government representatives shaping the future of blockchain and decentralised ecosystems.Deal-Making Opportunities: Engage with pre-qualified investors actively seeking the next big blockchain projects.Enterprise & Government Collaborations: Dive into discussions on regulatory frameworks, public-private partnerships, and enterprise adoption strategies for blockchain.Cutting-Edge Innovations: Witness live showcases of groundbreaking blockchain use cases, crypto solutions, and Web3 technologies from around the world.Dubai, known for its progressive blockchain policies and visionary leadership, is the perfect launchpad for the HODL brand. With Dubai’s commitment to becoming a global hub for blockchain and Web3 innovation, HODL is poised to make an unprecedented impact on the world of blockchain.QuotesMohammed Saleem, Founder and Chairman, Trescon, commented:“The rebranding of World Blockchain Summit to HODL marks a pivotal moment in our journey as we move beyond simply hosting events to becoming a true enabler of blockchain and Web3 innovation. With HODL, we aim to create a future-focused, results-driven platform that empowers projects, investors, and governments to collaborate meaningfully and shape the next era of decentralized technology.”Anil Kumar, COO, Trescon, added:“HODL isn’t just a rebrand—it’s a redefinition of what a blockchain event should be. It is a testament to our vision of facilitating real outcomes through deal-making, partnerships, and showcasing transformative blockchain solutions to the world. Dubai, with its ambitious blockchain agenda, is the perfect stage for this transition.”The Legacy of WBSFor nearly a decade, the World Blockchain Summit has led the way in blockchain adoption, creating a legacy as the longest-running Web3 event. The rebrand to HODL builds on this legacy, signalling a more strategic, business-centric approach to blockchain’s integration into industries and society.Join Us at HODL 2025 in DubaiMark your calendars for April 28-29, 2025, and join us in Dubai for HODL – The Vanguard of Blockchain and Beyond, where innovation meets opportunity.For more details and early registrations, visit: hodlsummit.com/dubai2025.About HODLHODL is an event by Trescon that supports the growth of the blockchain, crypto and Web3 ecosystem globally. It is the world's longest-running blockchain, crypto, and web 3-focused summit series. Since its inception in 2017, it has hosted more than 20 editions in 11 countries and strives to create the ultimate networking and deal flow platform for the Web3 ecosystem. Each edition brings together global leaders and emerging start-ups in the space, including investors, developers, IT leaders, entrepreneurs, government authorities, and others.About TresconTrescon is a global leader in business events, focusing on the adoption of emerging technologies and sustainable solutions. With a portfolio of industry-leading events, including HODL (formerly WBS), Trescon is dedicated to creating platforms that foster innovation, collaboration, and economic growth.Media Contact:Shadi DawiSenior DirectorPR, Comms., and Partnerships, Global & MEAE: shadi@tresconglobal.com | M: +971 55 498 4989 Copyright 2024 ACN Newswire via SeaPRwire.com.

HONG KONG, Nov 27, 2024 - (ACN Newswire via SeaPRwire.com) - The Hong Kong Export Credit Insurance Corporation (HKECIC) and Hong Kong Trade Development Council (HKTDC) jointly released a research study today, titled "Unleashing the Lucrative Potential of Cross-border E-commerce for Hong Kong Traders". The study revealed that 90% of surveyed companies anticipated that cross-border e-commerce could drive significant sales growth in the business in the next two years. However, the market-related challenges continue to persist, including intense market competition, complex customs clearance procedures and the management of returns and refunds. In light of these challenges, experts recommend developing appropriate online marketing and sales strategies, enhancing risk management and adopting efficient logistics and delivery practices to better seize the opportunities presented by cross-border e-commerce.Mr Terence Chiu, Commissioner of HKECIC, said, “The joint research study of the HKECIC and the HKTDC helps the industry in gaining deeper understanding of the latest development in expanding cross-border e-commerce, as well as outlining the challenges faced by businesses and the support they needed. While cross-border e-commerce has seen a significant growth in recent years, the study highlighted that the market remains highly competitive, and the ecosystem and related infrastructure still require further improvement. In addition, many e-commerce businesses have limited assets and insufficient collateral to secure financing from traditional banks and financial institutions, reflecting the ongoing challenges in the e-commerce environment. This year, the HKECIC has collaborated with a fintech and a reinsurance company, and also a bank to develop bespoke trade credit insurance solutions, aiming to provide coverage for trade loans to Hong Kong e-commerce businesses. These initiatives encourage and support local enterprises in securing trade financing and expanding into cross-border e-commerce. The HKECIC will actively seek collaboration with more financial institutions, in line with the 2024 Policy Address, to better support Hong Kong businesses in securing e-commerce export financing. By leveraging its expertise in trade credit insurance and risk management, the HKECIC is dedicated to assisting Hong Kong businesses in maintaining their competitive edge, helping them explore new overseas markets, mitigate trade risks and reduce operating costs.”Dr Patrick Lau, HKTDC Deputy Executive Director, said, “E-commerce has become a key driver of the global economy. The World Bank estimates that global B2C e-commerce sales will reach US$6 trillion by 2024, with Mainland China leading the way – over a quarter of retail consumer goods sales occur online. In collaboration with the HKECIC, the study aims to help Hong Kong businesses explore new markets and seize opportunities. The HKTDC will continue to support local companies in engaging with e-commerce and taking advantage of growth opportunities on the global stage.”From June to August 2024, the HKECIC and the HKTDC conducted phone and online interviews with 352 local trade and manufacturing companies to assess the development of Hong Kong companies’ cross-border e-commerce operations, while also detailing the challenges they face and identifying the support services they require.Driving significant sales growth in the next two yearsAs network technology has become more widespread, while electronic payment services are now ubiquitous and e-commerce platforms have come to offer an ever-expanding range of services, even new entrants and smaller businesses can easily develop cross-border e-commerce operations on a global basis. 90.0% of surveyed companies anticipated that cross-border e-commerce could raise their total sales revenue in the next two years.The surveyed companies in general indicated that cross-border e-commerce positively impacts their expansion plans whether via broader sales channels (69.0%), new market opportunities (50.3%), or enhanced brand awareness (48.9%).Reaching out to global markets: Focusing on the Mainland and ASEANHKTDC Principal Economist Wing Chu, who led the study, said, “The scope of cross-border e-commerce business for Hong Kong companies spans all parts of the world, covering markets, such as Mainland China (75.2%), ASEAN (53.0%), the US (42.2%), Japan (30.9%) and the EU (30.0%). Looking ahead, respondents generally agreed that, for the next two years, Mainland China (61.6%) and ASEAN (44.3%) offer the greatest growth potential. The surveyed companies generally hope to make use of risk management to meet market competitiveness and the challenges outlined, such as insurance for cargo transportation or payments (39.8%), e-commerce promotion (34.4%) and logistics services for both delivery and product returns (33.5%).”Coping with online and offline challengesCross-border e-commerce operators must confront a variety of practical issues relating to both online and offline procedures, including goods delivery, platform charges, exchange rates and refunds as well as market, regulation and financing issues.Of the companies surveyed, 38.4% said that customs clearance procedures in Mainland China and foreign markets are complex, with 31.3% indicating that product returns involve complicated procedures and / high costs, and 29.8% finding it difficult to manage practical issues, such as the international delivery of small orders.Regarding the issues of platform charges, exchange rates and refunds, the high commission rates charged by third-party e-commerce platforms and long payment periods were identified as challenges by 51.1% of respondents. Meanwhile, 46.6% said fluctuating exchange rates or high exchange costs were problems they faced during their cross-border e-commerce operations. 28.4% were concerned about the expansive costs about refund policy.In addition, companies must contend with a wide range of difficulties. Majority of the surveyed companies (84.9%) noted that developing cross-border e-commerce presented market-related challenges, such as keen market competition. Meanwhile, 54% indicated regulatory issues, and 41.2% encountered financial challenges.Leveraging Hong Kong's advantages to unlock global e-commerce opportunitiesIn addition to the questionnaire, HKTDC also interviewed a number of companies engaged in cross-border e-commerce or related businesses. According to expert’s opinion, though the mainland market is huge in scale, the competition is keen. Overseas opportunities abound, such as the advanced economies of Europe and America have mature online shopping markets and e-commerce markets in Southeast Asia.In addition, online sales strategies tailored to target markets are of prime importance, including the collaboration with KOL or influencers and using short-form videos to attract consumers.The study also highlighted Hong Kong's excellent logistics capabilities and extensive air cargo network as well as its well-developed financial markets and diverse financing services, which are well-suited to meeting the financial needs of e-commerce. Meanwhile, Hong Kong serves as an ideal gateway for foreign products entering Mainland China, with the Hong Kong brand enjoying a competitive edge in the region.Photo download: https://bit.ly/3Bb95BADr Patrick Lau, Deputy Executive Director, HKTDC (left) and Terence Chiu, Commissioner, HKECIC (right)Dr Patrick Lau, Deputy Executive Director, HKTDC (second left); Terence Chiu, Commissioner, HKECIC (second right); Wing Chu, Principal Economist, HKTDC (first left); and Cynthia Chin, General Manager, HKECIC (first right)References- HKTDC Research Portal https://research.hktdc.com/en- Unleashing the Lucrative Potential of Cross-border E-commerce for Hong Kong Traders https://research.hktdc.com/en/article/MTg1OTQ2Mzk3MwAbout HKECICThe HKECIC was established in 1966 under the Hong Kong Export Credit Insurance Corporation Ordinance (Chapter 1115). Through the provision of export credit insurance services, the HKECIC protects Hong Kong exporters who trade on credit terms with overseas buyers against non-payment risks and helps them conduct export business in a prudent manner. The HKSAR Government provides a guarantee of HK$80 billion for HKECIC’s contingent liability.About HKTDCThe Hong Kong Trade Development Council (HKTDC) is a statutory body established in 1966 to promote, assist and develop Hong Kong's trade. With 50 offices globally, including 13 in Mainland China, the HKTDC promotes Hong Kong as a two-way global investment and business hub. The HKTDC organises international exhibitions, conferences and business missions to create business opportunities for companies, particularly small and medium-sized enterprises (SMEs), in the mainland and international markets. The HKTDC also provides up-to-date market insights and product information via research reports and digital news channels. For more information, please visit: www.hktdc.com/aboutus. Follow us on Twitter @hktdc and LinkedInMedia enquiriesHKECICCorporate Communication DivisionTina NgTel: (852) 2732 9998Email: tina.ng@hkecic.comHKTDCCorporate Communication & Marketing DepartmentSharon HaTel: (852) 2584 4575Email:sharon.mt.ha@hktdc.orgYuan Tung Financial Relations LimitedLouise SongTel: (852) 3248 5691Email: lsong@yuantung.com.hk Copyright 2024 ACN Newswire via SeaPRwire.com.

KUCHING, MALAYSIA, Nov 28, 2024 - (ACN Newswire via SeaPRwire.com) - Industrialised building systems specialist, Sarawak Consolidated Industries Berhad ("SCIB" or the "Company") is pleased to announce its unaudited financial results for the first quarter of the fiscal year 2025 (“Q1 FY2025”). The Company reported a revenue of RM45.1 million, marking a 14.6% year-on-year increase compared to RM39.4 million in Q1 FY2024. The growth in revenue is largely due to the increased recognition of construction works done from ongoing projects. Ku Chong Hong, Managing Director of SCIBAs for Q1FY2025, SCIB's Manufacturing division continues to play a pivotal role in the Company’s performance, contributing RM32.5 million to the total revenue, a 9.9% increase from RM29.6 million in Q1 FY2024. This growth was primarily driven by increased sales of foundation piles and Industrialised Building System (“IBS”) products, especially for major projects such as the Kuching Urban Transportation System (“KUTS”), the Sarawak Second Trunk Road (“STR”) and school projects in Sarawak.Profit Before Tax (“PBT”) for the manufacturing segment stood at RM3.8 million. Meanwhile, the Construction/Engineering, Procurement, Construction and Commissioning (“EPCC”) division reported revenue of RM12.6 million, an increase from RM9.8 million in the same quarter last year. However, the segment recorded a Loss Before Tax (“LBT”) of RM2.0 million due to unanticipated unrealised foreign exchange loss recognised. The division remains focused on delivering ongoing projects while exploring new opportunities for expansion.During the quarter, SCIB maintained its commitment to strengthening its financial foundation and broadening its project portfolio. Additionally, SCIB had recently acquired a 2.49-hectares land parcel at Bintulu Sibiu Road, Bintulu, for RM9.2 million, followed by another parcel of 7.3-hectares land in Jalan Bintulu-Sibu as part of its plan to collaborate with developers for residential housing projects that utilise SCIB’s high-quality products and industry expertise, while expanding SCIB’s products and services offering to serve the fundamental needs of the Sarawak market.Mr. Ku Chong Hong, Managing Director of SCIB, commented, “The results of Q1 FY2025 reflect the challenges of a dynamic economic environment. However, we remain steadfast in our commitment to strengthening the financial foundation of the Company. Besides targeting to secure projects consistently, the recent securing of financial facilities from SME Bank and the proposed private placement of 10.0% of SCIB’s total issued shares underscore our focus on enhancing our cash position and ensuring financial stability to support our operational and strategic initiatives."Looking ahead, SCIB remains optimistic about Malaysia’s construction sector, bolstered by the record allocation in Budget 2025 of RM421 billion, including RM86 billion for development expenditure. The RM5.9 billion allocated for Sarawak, aimed at upgrading public infrastructure such as schools, healthcare centres, and airports, as well as large-scale projects like the Sabah-Sarawak Link Road (“SSLR”) and the North Coastal Highway, aligns seamlessly with SCIB’s expertise and strategic direction. The Company is poised to leverage its manufacturing capabilities and strategic initiatives to secure a strong foothold in both local and regional markets, ensuring sustainable growth and long-term value for its stakeholders.ABOUT SARAWAK CONSOLIDATED INDUSTRIES BERHADSarawak Consolidated Industries Berhad (“SCIB”) was founded in 1975 and has evolved from a small enterprise into a reputable Group of companies listed on the Main Market of Bursa Malaysia Securities Berhad. Currently, SCIB is operating three factories in Kuching, Sarawak, one factory in the Pending Industrial Estate and two factories in the Demak Laut industrial park.SCIB is well known for professional management and has long history of innovative ideas and technological advances. Coupled with its wealth of experience and research acquired in more than three decades, SCIB offers its clients in-depth expertise through a combination of technology, efficiency and speed.For more information, visit scib.com.my.Issued By: Swan Consultancy Sdn. Bhd. on behalf of Sarawak Consolidated Industries BerhadFor more information, please contact:Jazzmin WanEmail: j.wan@swanconsultancy.bizStephanie ChowEmail: s.chow@swanconsultancy.biz Copyright 2024 ACN Newswire via SeaPRwire.com.

Download images: https://shorturl.at/o22GsHONG KONG, Nov 27, 2024 - (ACN Newswire via SeaPRwire.com) - As the holiday season approaches, Champion REIT (Stock Code: 2778) is pleased to announce its “Green Vitality” festive campaign at its all-in-one beauty landmark, LANGHAM BEAUTY. It has unveiled the immersive sustainable Christmas decorations in collaboration with a local environmental art curation studio*. A Beauty Empties Recycling Programme was also launched, with a goal of promoting green lifestyle through innovative and diverse art while sharing festive joy with the community.Embracing Sustainability with Immersive Christmas DecorationsThis green Christmas campaign at LANGHAM BEAUTY presents "The Urban Oasis", a sustainable art installation created in collaboration with a local environmental art curation studio. This immersive display symbolises a tranquil green oasis amidst the bustling city, encouraging the public to connect with nature. Located on L1 of Langham Place, the nature-infused display features 250 recycled plastic decorations and reusable steel structures. As stepping in, visitors will be greeted by the soothing sounds of chirping birds and the fresh scent of Christmas trees, inviting them into an immersive natural healing experience. To promote sustainability, these Christmas trees and over 60% of the plants will be replanted and upcycled after the event, giving these beautiful plants a second life.*Earthero Studio is an environmental curation and consulting firm that uses art as a medium to convey ecological messages. In 2022, they organized Asia's first sustainable fashion art exhibition. The studio also operates a clothing brand that upcycles surplus fabrics and second-hand items into new, fashionable pieces.Partnering with V Cycle to Launch the Beauty Empties Recycling ProgrammeAnother highlight is the launch of “Green Vitality Beauty Empties Recycling Programme" in partnership with the eco-conscious social enterprise V Cycle. Through this initiative, the public can drop off empty plastic beauty product containers at the nature-inspired collection point on L2 of LANGHAM BEAUTY, from which the collected empty bottles will be processed and transformed into valuable resources by V Cycle. This lush greenery backdrop also provides a perfect spot for photos while encouraging customers to embrace a greener lifestyle through collective recycling efforts.Introducing a New Beauty Zone with Leading International BrandsLANGHAM BEAUTY has recently completed its expansion with a new zone featuring a selection of high-quality international beauty brands. The new additions include Hong Kong's first Valentino Beauty counter; Hourglass, the American vegan makeup brand committed to animal rights; JSM Beauty, founded by South Korean legendary makeup artist Jung Saem Mool; Japan's prestigious skincare brand Albion; and Europe's luxurious Helena Rubinstein. These brands offer diverse beauty choices and exceptional customer experiences, reinforcing LANGHAM BEAUTY's status as a premier one-stop-for-all beauty destination.Innovative Services with the First 'Shop-to-Point' Seamless ExperienceTo make holiday shopping more convenient, LANGHAM BEAUTY has partnered with SF Express Hong Kong to launch the first beauty-themed "Shop-to-Point" service station in the city, offering free same-day delivery* with no minimum spend. Additionally, our e-store continues to expand product selection, ensuring a seamless shopping experience both in-store and online. *Yau Tsim Mong District Exclusive. Order before 3pm for same-day delivery.From left: Ms. Christina Hau, CEO of Champion REIT and Ms Grace Chan Hoi Lam, Celebrity unveil the sustainable Christmas art installationFrom left: Mr Eric Swinton, Founder & CEO of V Cycle; Ms Bertha Shum, CEO of Earthero Studio;Ms Christina Hau, CEO of Champion REIT; Ms Grace Chan Hoi Lam, Celebrity;Ms Iris Li, General Manager of LANGHAM BEAUTY join the kick-off ceremonyThis Christmas, join us at LANGHAM BEAUTY to celebrate a sustainable holiday. Let's bring green ideas to life through our collective efforts and immerse ourselves in the creativity and vibrant green aesthetics of LANGHAM BEAUTY!LANGHAM BEAUTY “The Urban Oasis” Eco Christmas Art InstallationDate and time:27 November 2024 to 2 January 2025Monday to Thursday: 11:00 AM - 10:00 PMFriday to Sunday: 11:00 AM - 10:30 PMVenue:L1, Langham Place, Mongkok LANGHAM BEAUTY Green Vitality Beauty Empties Recycling ProgrammeDate and time:27 November 2024Monday to Thursday: 11:00 AM - 10:00 PMFriday to Sunday: 11:00 AM - 10:30 PMRecollection point:LANGHAM BEAUTY L2, Langham Place, MongkokAbout Champion REIT (2778)Champion Real Estate Investment Trust is a trust formed to own and invest in income-producing office and retail properties. The Trust focuses on Grade-A commercial properties in prime locations. It currently offers investors direct exposure to nearly 3 million sq. ft. of prime office and retail area. These include two Hong Kong landmark properties, Three Garden Road and Langham Place, as well as a joint venture stake in 66 Shoe Lane in Central London. The Trust has been awarded the top five-star rating by GRESB since 2023.About Langham BeautyLangham Beauty is a premier beauty concept store located on L1 & L2 of Langham Place in Mong Kok. It features over 60 top-tier brands in beauty, skincare, fragrance, haircare, and body care, including ARMANI BEAUTY, CHANEL BEAUTÉ, DIOR BEAUTY, ESTÉE LAUDER, LANCÔME, SHISEIDO, SK-II, and VALENTINO BEAUTY etc. Our mission is to transform customers' beauty journeys, providing a one-stop shopping experience that caters to the beauty aspirations of every woman. At Langham Beauty, we believe that staying true to oneself and embracing nature are the first step to achieving confidence and natural beauty.Langham Beauty breaks conventions by integrating three essential elements: human, nature, and technology, to present a diverse aesthetic. We are committed to environmental sustainability in beauty and leverage technological innovations to balance beauty consumption while giving back to nature. Langham Beauty serves as a bridge between luxury beauty and the natural world, ensuring that our customers experience the essence of " Be True in Life, Be Kind to Earth, Be a Beautiful You" while nurturing both their outer and inner beauty.​​About Langham PlaceLangham Place, under Champion REIT, is strategically situated in the bustling heart of Mong Kok, Kowloon. This iconic 15-story landmark serves as a premier destination for fashion enthusiasts. Boasting nearly 200 retail outlets, Langham Place offers a diverse array of international and local fashion brands, an eclectic mix of dining options, a state-of-the-art cinema, and the expansive beauty concept store, LANGHAM BEAUTY. The mall elevates the social and shopping experience by hosting a variety of cultural and creative promotional activities throughout the year. Notably, Langham Place is the first property in Hong Kong to achieve the EDGE (Excellence in Design for Greater Efficiencies) certification for existing buildings and has been honored with the Platinum rating by BEAM Plus, the highest accolade for existing buildings. Copyright 2024 ACN Newswire via SeaPRwire.com.

Brisbane, Queensland, Australia--(ACN Newswire via SeaPRwire.com - November 27, 2024) - Graphene Manufacturing Group Ltd. (TSXV: GMG) ("GMG" or the "Company") is pleased to announce that THERMAL-XR® has been awarded 'Product of the Year' during the AIRAH 2024 Awards that took place on Thursday, November 21st, 2024 in Melbourne, Australia. The AIRAH Awards celebrate outstanding achievements from across Australia's HVAC&R building services industry.Figure 1To view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/8082/231582_fd157079640dd8d3_001full.jpgGMG's Managing Director and CEO, Craig Nicol, commented: "We are truly honored that THERMAL-XR® has been recognized with the Product of the Year Award at the AIRAH 2024 Awards. This achievement is a direct result of the dedication and innovation of our team, and it reinforces our commitment to advancing energy efficiency and sustainability in the HVAC industry. We believe THERMAL-XR® represents the future of high-performance solutions, and we are proud to contribute to a more sustainable and energy-efficient world."Figure 2To view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/8082/231582_fd157079640dd8d3_002full.jpgAbout AIRAH AwardsThe AIRAH Awards provide our industry with the opportunity to reflect, applaud, and raise a toast to our peers and their achievements - from promising future leaders to established sector veterans; from the finest new projects to the best retrofits; as well as the greatest in refrigeration, renewable energy, and research. Independent industry specialists determine a shortlist of finalists, from which a winner is selected by an expert judging panel. This rigorous and impartial process makes the AIRAH Awards the most highly prized accolades in Australia's HVAC&R building services industry.About THERMAL-XR® powered by GMG Graphene:THERMAL-XR® COATING SYSTEM is a unique method of improving the conductivity of corroded heat exchange surfaces and improving and maintaining the performance of new units at peak levels. The process coats and protects heat exchange surfaces while improving and rebuilding the lost corroded thermal conductivity and increasing the heat transfer rate by leveraging the physics of GMG Graphene, resulting in an efficiency improvement and a potential power reduction.THERMAL-XR ENHANCE® is powered by GMG Graphene. PATENT PENDINGAbout GMG www.graphenemg.comGMG is a clean-technology company which seeks to offer energy saving and energy storage solutions, enabled by graphene, including that manufactured in-house via a proprietary production process. GMG has developed a proprietary production process to decompose natural gas (i.e. methane) into its elements, carbon (as graphene), hydrogen and some residual hydrocarbon gases. This process produces high quality, low cost, scalable, 'tuneable' and low/no contaminant graphene suitable for use in clean-technology and other applications.The Company's present focus is to de-risk and develop commercial scale-up capabilities, and secure market applications. In the energy savings segment, GMG has focused on graphene enhanced heating, ventilation and air conditioning ("HVAC-R") coating (or energy-saving coating), lubricants and fluids.In the energy storage segment, GMG and the University of Queensland are working collaboratively with financial support from the Australian Government to progress R&D and commercialization of graphene aluminium-ion batteries ("G+AI Batteries").GMG's 4 critical business objectives are:Produce Graphene and improve/scale cell production processesBuild Revenue from Energy Savings ProductsDevelop Next-Generation BatteryDevelop Supply Chain, Partners & Project Execution CapabilityFor further information please contact:Craig Nicol, Chief Executive Officer & Managing Director of the Company at craig.nicol@graphenemg.com, +61 415 445 223Leo Karabelas at Focus Communications Investor Relations, leo@fcir.ca, +1 647 689 6041Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accept responsibility for the adequacy or accuracy of this news release.To view the source version of this press release, please visit https://www.newsfilecorp.com/release/231582 Copyright 2024 ACN Newswire via SeaPRwire.com.